Inhibiting interleukin-6 (IL-6), whose secretion leads to an overactive immune response, improves the treatment of severe COVID-19 patients by avoiding cytokine release syndrome (CRS) (Moore and June, 2020). Here, IL6 is linked to congenital rubella syndrome.